Recently, BGI Genomics Co.,Ltd. (Hereinafter referred to as "BGI Genomics") was selected as the "2022 ESG Best Social Responsibility Enterprise" by China.org.cn in the "2022(second) ESG Practice Survey of Chinese Enterprises" selection.

"ESG Practice Research of Chinese Enterprises" is organized by China Net Finance and held for the second time in 2022. Through voluntary application or recommendation by others and expert review, five outstanding cases of 2022 ESG enterprise, ESG Brand Influence Enterprise, ESG Best Environmental Responsibility (E) Practice Enterprise, ESG Best Social responsibility (S) practice enterprise, and ESG Best Corporate Governance (G) practice enterprise are selected. In view of BGI's excellent performance in environmental protection, social responsibility and corporate governance, the company was awarded the 2022 ESG Best Social Responsibility Enterprise.

Since 2018, BGI Genomics has issued four social responsibility reports in succession. The company practices social responsibility in many aspects, such as responsible governance, sound operation, innovative development, quality management, customer service, caring for employees, precise poverty alleviation, public welfare funds, public welfare assistance and so on, and constantly promotes the in-depth implementation of corporate social responsibility.

In 2020, the Company's 2019 Annual Social Responsibility Report was selected as the "Excellent Cases of 2019 Annual Report of Listed Companies on the Growth Enterprise Market of Shenzhen Stock Exchange", and in 2022, BGI was selected as the "ESG Excellent Practice Cases of Listed Companies" compiled by the China Association of Listed Companies.

In 2022, the company will continue to actively fulfill its social responsibilities, through social welfare projects such as birth defects prevention and control, cancer prevention and control, and health care programs, so that precision medicine will benefit more people and help the implementation of "Healthy China 2030".

In terms of birth defect prevention and control, the company has organized more than 100 free clinic activities in conjunction with local health committees, disabled persons' federations, medical institutions and public welfare organizations on several public welfare days such as "National Ear Care Day", "World Down Syndrome Day", "World Hemophilia Day", "World Poor Day" and "National Eye Care Day" in 2022. For eligible patients and families with genetic diseases, more than 1,000 cases of free genetic testing and genome counseling services are provided.

In terms of thalassemia prevention and control, the company has adopted advanced independent platform sequencing technology, and has launched the "thalassemia prevention and control livelihood project" in Guangdong, Guangxi, Yunnan, Guizhou, Hunan, Jiangxi and other provinces, with a cumulative t est sample of more than 680,000 cases. The project detected more than 170 types of thalassemia gene variations and more than 180 abnormal hemoglobin variations, which effectively improved the prevention and control effect of thalassemia.

In terms of the treatment of thalassemia patients, the company cooperated with China Foundation and other organizations and public welfare organizations to carry out a free clinic activity with the theme of "Care for thalassemia children, Together for the Future", providing thalassemia patients and their families with free 508 types of thalassemia gene testing, genome consultation and free HLA matching services, helping more poor families to regain the hope of life and giving birth to healthy babies. By the end of June 2022, the program has provided free HLA matching services to more than 16,000 people from nearly 5,600 impoverished families, and a total of 591 patients have been fully matched.

In the aspect of cancer prevention and control, in order to implement the "Healthy China strategy" and promote the advancement of disease prevention and control, the company, together with the Rehabilitation Association of China Anti-Cancer Association and Beijing Aipu Patient Care Foundation, held a series of online free diagnosis activities of "medical road walking the world without cancer" to pass on the concept and knowledge of scientific anti-cancer to patients. More than 19,000 cancer patients participated online. Doctors and patients work together to build confidence and share the benefits of medical scientific and technological progress.

In the "Cancer Prevention and Treatment Publicity Week", the company cooperated with the science committee of China Anti-Cancer Association to carry out the free diagnosis activity with the theme of "Paying attention to tumor early screening, helping the world to be cancer-free", and provided more than 1,000 cases of free gene detection of tumor early screening for the appropriate age group, making the concept of "early screening, early diagnosis and early treatment" more popular.

In addition, the company set up a public welfare special project of "No Cancer in the World", and Mr. Wang Jian, chairman of the company, Mr. Yin Ye, vice chairman of the company, and Mr. Zhu Shida, deputy general manager of the company, all donated 1 million yuan to the project.

BGI Genomics has always been adhering to the mission of "Omics for All", adhering to the principle of "Low Price for People", continuing to develop new projects of gene health screening for people's livelihood throughout the country, steadily promoting the application of gene technology for people's livelihood, and contributing to the implementation of the strategy of healthy China.

日前，在中国网“2022(第二届)中国企业ESG实践调研”评选活动中，深圳华大基因股份有限公司（以下简称“华大基因”）成功入选“2022年度ESG最佳社会责任企业。

“中国企业ESG实践调研”活动由中国网财经主办，2022年已是第二届举办。优秀案例征集通过主动报名或他人推荐，经专家评审，共甄选出2022年度ESG企业、年度ESG品牌影响力企业、年度ESG最佳环境责任(E)实践企业、年度ESG最佳社会责任(S)实践企业、年度ESG最佳公司治理(G)实践企业共五大类优秀案例。鉴于华大基因在环境保护、社会责任和公司治理方面的优良表现，公司获评为2022年度ESG最佳社会责任企业。

从2018年至今，华大基因已连续发布四份社会责任报告。公司围绕责任治理、稳健经营、创新发展、质量管理、服务客户、关爱员工、精准扶贫、公益基金、公益救助等多个方面践行社会责任，不断促进公司社会责任深入履行。

2020年，公司《2019年度社会责任报告》入选“深交所创业板上市公司2019年年报优秀案例”，2022年，华大基因入选中国上市公司协会组织汇编的《上市公司ESG优秀实践案例》。

2022年，公司继续积极履行社会责任，通过出生缺陷防控、肿瘤防控等社会公益项目和健康关爱计划等，让精准医学普惠更多民众，助力“健康中国2030”的实施落地。

在出生缺陷防控方面，公司在2022年的“全国爱耳日”“世界唐氏综合征日”“世界血友病日”“世界地贫日”“全国爱眼日”等多个公益日，联合各地卫健委、残联、医疗机构、公益组织等单位举办了百余场义诊活动，为符合要求的遗传性疾病患者及家庭提供千余例免费的基因检测及基因组咨询服务。

在地中海贫血防控方面，公司采用先进的自主平台测序技术，已在广东、广西、云南、贵州、湖南、江西等多个省份启动“地中海贫血防控民生项目”，累计检测样本超68万例。项目共检出地贫基因变异类型超过170种，异常血红蛋白变异超过180种，有效提升了地贫的防控效果。

在地中海贫血患者救助方面，公司联合华基金等机构和公益组织开展以“关爱地贫儿，一起向未来”为主题的义诊活动，为符合要求的地中海贫血患者及家庭提供免费的508种型别地贫基因检测、基因组咨询及免费HLA配型服务，帮助更多地贫家庭重拾生活的希望，孕育健康宝宝。截至2022年6月底，该项目已累计为近5,600个地贫家庭超过16,000余人提供了免费HLA配型检测服务，共计591名患者配型全相合。

在肿瘤防控方面，为践行“健康中国战略”，推进疾病防控关口前移，公司联合中国抗癌协会康复会、北京爱谱患者关爱基金会，举办了“医路同行天下无癌”系列线上义诊活动，向患者传递科学抗癌的理念和知识，超19,000名肿瘤患者在线参与，医患携手共立信心，共享医疗科技进步的福祉。

在“肿瘤防治宣传周”，公司携手中国抗癌协会科普专委会开展主题为“关注肿瘤早筛，助力天下无癌”义诊活动，为适龄人群提供了千余例的免费肿瘤早筛基因检测，使“早筛早诊早治”的理念深入人心。

此外，公司成立了“天下无癌”公益专项，公司董事长汪建先生、副董事长尹烨先生、副总经理朱师达先生均为该项目个人捐赠100万元。

华大基因始终秉承“基因科技造福人类”的使命，坚持“持续低价惠民”原则，在全国各地继续开拓新的基因健康筛查民生项目，稳步推进基因科技的民生应用，为健康中国战略实施贡献着科技的力量。